TELOMIUM.COM: Keyword Density Checker

Total words: 739 | 2-word phrases: 195 | 3-word phrases: 202 | 4-word phrases: 205

PAGE INFO

Title	Try to keep the title under 60 characters (30 characters) Telomium – Immunotherapy
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (41 characters) Bringing Successful Immunotherapy for All

#	Keyword	Frequency	Density
1	lead product tlvx01	2	0.99%
2	nevepowered by wordpress	2	0.99%
3	our lead product	2	0.99%
4	skip to content	1	0.50%
5	telomerase it has	1	0.50%
6	allow it to	1	0.50%
7	it to fight	1	0.50%
8	it has the	1	0.50%
9	beyond its standard	1	0.50%
10	diseases beyond its	1	0.50%
11	system to allow	1	0.50%
12	its standard capacity	1	0.50%
13	ribonucleoprotein based on	1	0.50%
14	firstinclass ribonucleoprotein based	1	0.50%
15	telomium develops vaccines	1	0.50%
16	develops vaccines of	1	0.50%
17	to allow it	1	0.50%
18	the immune system	1	0.50%
19	immune system to	1	0.50%
20	highly optimised immunotherapies	1	0.50%
21	beyond oncology as	1	0.50%
22	oncology as well	1	0.50%
23	trigger an autoimmune	1	0.50%
24	to trigger an	1	0.50%
25	telomium develops highly	1	0.50%
26	develops highly optimised	1	0.50%
27	formulation to trigger	1	0.50%
28	of a completely	1	0.50%
29	ideal formulation to	1	0.50%
30	the ideal formulation	1	0.50%

#	Keyword	Frequency	Density
1	our lead product tlvx01	2	0.98%
2	prominent ability of ribonucleoproteins	1	0.49%
3	telomium develops highly optimised	1	0.49%
4	system to allow it	1	0.49%
5	immune system to allow	1	0.49%
6	the immune system to	1	0.49%
7	reprograms the immune system	1	0.49%
8	technology reprograms the immune	1	0.49%
9	our technology reprograms the	1	0.49%
10	lead product tlvx01 is	1	0.49%
11	product tlvx01 is a	1	0.49%
12	tlvx01 is a firstinclass	1	0.49%
13	is a firstinclass ribonucleoprotein	1	0.49%
14	a firstinclass ribonucleoprotein based	1	0.49%
15	develops highly optimised immunotherapies	1	0.49%
16	firstinclass ribonucleoprotein based on	1	0.49%
17	allow it to fight	1	0.49%
18	telomerase it has the	1	0.49%
19	beyond oncology as well	1	0.49%
20	immunotherapies beyond oncology as	1	0.49%
21	and immunotherapies beyond oncology	1	0.49%
22	it has the ideal	1	0.49%
23	has the ideal formulation	1	0.49%
24	the ideal formulation to	1	0.49%
25	that contains oncology products	1	0.49%
26	pipeline that contains oncology	1	0.49%
27	the prominent ability of	1	0.49%
28	on a pipeline that	1	0.49%
29	working on a pipeline	1	0.49%
30	to allow it to	1	0.49%
31	diseases beyond its standard	1	0.49%
32	we are working on	1	0.49%
33	ribonucleoproteins which have a	1	0.49%
34	ability of ribonucleoproteins to	1	0.49%
35	of ribonucleoproteins to bypass	1	0.49%
36	ribonucleoproteins to bypass immune	1	0.49%
37	tolerance against pathogenic tissues	1	0.49%
38	immune tolerance against pathogenic	1	0.49%
39	of immune tolerance against	1	0.49%
40	break of immune tolerance	1	0.49%

#	URL	Whois	Check
1	https://www.youtube.com/watch?v=1Rciiy6BjvE	Whois	youtube.com
2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371274/	Whois	nih.gov
3	https://themeisle.com/themes/neve/	Whois	themeisle.com
4	https://wordpress.org	Whois	wordpress.org
5	https://themeisle.com/themes/neve/	Whois	themeisle.com
6	https://wordpress.org	Whois	wordpress.org